Literature DB >> 29999200

Recent Progress on Manganese-Based Nanostructures as Responsive MRI Contrast Agents.

Lorena García-Hevia1, Manuel Bañobre-López1, Juan Gallo1.   

Abstract

Manganese-based nanostructured contrast agents (CAs) entered the field of medical diagnosis through magnetic resonance imaging (MRI) some years ago. Although some of these Mn-based CAs behave as classic T1 contrast enhancers in the same way as clinical Gd-based molecules do, a new type of Mn nanomaterials have been developed to improve MRI sensitivity and potentially gather new functional information from tissues by using traditional T1 contrast enhanced MRI. These nanomaterials have been designed to respond to biological environments, mainly to pH and redox potential variations. In many cases, the differences in signal generation in these responsive Mn-based nanostructures come from intrinsic changes in the magnetic properties of Mn cations depending on their oxidation state. In other cases, no changes in the nature of Mn take place, but rather the nanomaterial as a whole responds to the change in the environment through different mechanisms, including changes in integrity and hydration state. This review focusses on the chemistry and MR performance of these responsive Mn-based nanomaterials.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  contrast agents; magnetic resonance imaging; manganese; nanostructures

Year:  2018        PMID: 29999200     DOI: 10.1002/chem.201802851

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  11 in total

Review 1.  Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.

Authors:  Xiaoxia Cai; Qingxia Zhu; Yun Zeng; Qi Zeng; Xueli Chen; Yonghua Zhan
Journal:  Int J Nanomedicine       Date:  2019-10-21

Review 2.  Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies.

Authors:  Shuang Liang; Guangfu Liao; Wenzhen Zhu; Li Zhang
Journal:  Biomater Res       Date:  2022-07-06

Review 3.  Recent Advances in Nanotheranostic Agents for Tumor Microenvironment-Responsive Magnetic Resonance Imaging.

Authors:  Longhai Jin; Chenyi Yang; Jianqiu Wang; Jiannan Li; Nannan Xu
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

4.  Highly water-dispersible calcium lignosulfonate-capped MnO nanoparticles as a T 1 MRI contrast agent with exceptional colloidal stability, low toxicity and remarkable relaxivity.

Authors:  Mahdi Arian; Ali Zamanian; Salman Taheri
Journal:  RSC Adv       Date:  2019-12-06       Impact factor: 4.036

Review 5.  New Strategies in the Design of Paramagnetic CAs.

Authors:  Alessio Smeraldo; Paolo A Netti; Enza Torino
Journal:  Contrast Media Mol Imaging       Date:  2020-09-27       Impact factor: 3.161

6.  L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.

Authors:  Jiali Li; Xue Jiang; Lihuan Shang; Zhen Li; Conglian Yang; Yan Luo; Daoyu Hu; Yaqi Shen; Zhiping Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  GMBP1-conjugated manganese oxide nanoplates for in vivo monitoring of gastric cancer MDR using magnetic resonance imaging.

Authors:  Wenhua Zhan; Xiaoxia Cai; Hairui Li; Getao Du; Hao Hu; Yayan Wu; Lin Wang
Journal:  RSC Adv       Date:  2020-04-03       Impact factor: 4.036

8.  Manganese-Based Targeted Nanoparticles for Postoperative Gastric Cancer Monitoring via Magnetic Resonance Imaging.

Authors:  Ke Li; Peng Li; Yang Wang; Shuang Han
Journal:  Front Oncol       Date:  2020-10-19       Impact factor: 6.244

Review 9.  Smart magnetic resonance imaging-based theranostics for cancer.

Authors:  Beatriz Brito; Thomas W Price; Juan Gallo; Manuel Bañobre-López; Graeme J Stasiuk
Journal:  Theranostics       Date:  2021-08-07       Impact factor: 11.556

Review 10.  Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics.

Authors:  Mónica Cerqueira; Efres Belmonte-Reche; Juan Gallo; Fátima Baltazar; Manuel Bañobre-López
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.